Shanxi Zhendong Pharmaceutical
Shanxi Zhendong Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sales of pharmaceutical drugs in China. It offers drugs for various fields, including tumors, dermatology, digestion, urology, and cardio-cerebral drugs. The company also provides Chinese herbal medicines. Shanxi Zhendong Pharmaceutical Co.,Ltd was founded in 1995 and is b… Read more
Shanxi Zhendong Pharmaceutical (300158) - Total Liabilities
Latest total liabilities as of September 2025: CN¥882.65 Million CNY
Based on the latest financial reports, Shanxi Zhendong Pharmaceutical (300158) has total liabilities worth CN¥882.65 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanxi Zhendong Pharmaceutical - Total Liabilities Trend (2007–2024)
This chart illustrates how Shanxi Zhendong Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Shanxi Zhendong Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Shanxi Zhendong Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sanhe Tongfei Refrigeration Co. Ltd.
SHE:300990
|
China | CN¥675.50 Million |
|
Banca Farmafactoring S.p.A.
LSE:0RON
|
UK | €10.28 Billion |
|
Huayi Brothers Media Corp
SHE:300027
|
China | CN¥2.29 Billion |
|
Beijing Jiaxun Feihong Electrical Co Ltd
SHE:300213
|
China | CN¥876.89 Million |
|
SÜSS MicroTec SE
PINK:SESMF
|
USA | $218.69 Million |
|
PT Indo Tambangraya Megah Tbk
F:3IB
|
Germany | €475.20 Million |
|
Sunway Co Ltd
SHG:603333
|
China | CN¥797.05 Million |
|
Kura Oncology Inc
NASDAQ:KURA
|
USA | $564.23 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down Shanxi Zhendong Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanxi Zhendong Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanxi Zhendong Pharmaceutical (2007–2024)
The table below shows the annual total liabilities of Shanxi Zhendong Pharmaceutical from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.32 Billion | +27.60% |
| 2023-12-31 | CN¥1.04 Billion | -21.94% |
| 2022-12-31 | CN¥1.33 Billion | -34.89% |
| 2021-12-31 | CN¥2.04 Billion | +3.50% |
| 2020-12-31 | CN¥1.97 Billion | +33.64% |
| 2019-12-31 | CN¥1.47 Billion | -20.32% |
| 2018-12-31 | CN¥1.85 Billion | -10.00% |
| 2017-12-31 | CN¥2.06 Billion | +28.24% |
| 2016-12-31 | CN¥1.60 Billion | -21.42% |
| 2015-12-31 | CN¥2.04 Billion | +129.67% |
| 2014-12-31 | CN¥888.23 Million | +5.91% |
| 2013-12-31 | CN¥838.64 Million | +22.56% |
| 2012-12-31 | CN¥684.26 Million | +72.18% |
| 2011-12-31 | CN¥397.40 Million | +2.13% |
| 2010-12-31 | CN¥389.13 Million | +37.08% |
| 2009-12-31 | CN¥283.87 Million | +23.43% |
| 2008-12-31 | CN¥229.98 Million | -20.77% |
| 2007-12-31 | CN¥290.28 Million | -- |